Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
Phase of Trial: Phase III
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ocular inflammation; Ocular pain; Postoperative inflammation; Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors Ocular Therapeutix
- 11 Jul 2017 According to an Ocular Therapeutix media release, the company has received CRL from the U.S. FDA, regarding its resubmission of a NDA for dexamethasone insert 0.4mg for the treatment of ocular pain following ophthalmic surgery. It states, the FDA cannot approve the NDA in its present form due to the deficiencies in manufacturing processes and analytical testing related to manufacture of drug product for commercial production identified during a pre-NDA approval inspection in May 2017.
- 11 May 2017 According to an Ocular Therapeutix media release, the upcoming PDUFA (Prescription Drug User Fee Act (PDUFA)) date 19 Jul 2017 set by the the U.S. Food and Drug Administration (FDA) is for a New Drug Application (NDA) for the treatment of ocular pain following ophthalmic surgery based on a phase 2 trial (NCT01666210) and two phase 3 trials (NCT02089113 and NCT02034019) independent of the third and most recent phase 3 study results.
- 11 May 2017 According to an Ocular Therapeutix media release, results of the pooled analysis from three phase 3 clinical trials evaluating the integrated efficacy and safety of DEXTENZA (NCT02089113, NCT02034019 and NCT02736175), presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (2017).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History